Warfarin Aripiprazole

Drugs that may be affected by itraconazole include alfentanil, almotriptan, alprazolam, amphotericin B, aripiprazole, benzodiazepines, buspirone, busulfan, calcium blockers, carbamazepine, cilostazol, cisapride, corticosteroids, cyclosporine, digoxin, disopyramide, docetaxel, dofetilide, eletriptan, epierenone, ergot alkaloids, haloperidol, HMG-CoA reductase inhibitors, hydantoins (phenytoin), hypoglycemic agents, oral midazolam, phosphodiesterase type 5 inhibitors, pimozide, polyenes, protease inhibitors, quinidine, rifamycins, sirolimus, tacrolimus, tolterodine, triazolam, trimetrexate, vinca alkaloids, warfarin, and zolpidem. 

To date, the combined olanzapine-warfarin regimen has not revealed any pharmacokinetic interactions. No interactions have been reported to date between aripiprazole and... 

Aripiprazole plasma levels are increased by inhibitors, and decreased by inducers, of CYP3A4. Quinidine increases aripiprazole levels. The manufacturers advise caution with drugs that can prolong the QT intervaL Food and famotidine do not have a clinically relevant effect on the pharmacokinetics of aripiprazole, and aripiprazole does not affect the pharmacokinetics of dextromethorphan, omeprazole, and warfarin. 

Aripiprazole 10 to 30 mg daily had no significant effects on the metabolism of dextromethorphan (CYP2D6 and CYP3A4 substrate), warfarin (CYP2C9 substrate) and omeprazole (CYP2C19 substrate). Aripiprazole is not expected to affect CYPl A2-mediated metabolism. The manufacturers therefore conclude that aripiprazole is unlikely to have clinically significant interactions with drugs that are substrates for these isoenzymes. ... 

---